Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells

Kaech, S. M., Tan, J. T., Wherry, E. J., Konieczny, B. T., Surh, C. D., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni1009 · Cited by 1,830 · see citing works

SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx

Laguette, N., Sobhian, B., Casartelli, N., Ringeard, M., Chable-Bessia, C., Ségéral, E., Yatim, A., Emiliani, S., Schwartz, O., & Benkirane, M. (2011) · Nature · doi:10.1038/nature10117 · Cited by 1,511 · see citing works

Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein

Hrecka, K., Hao, C., Gierszewska, M., Swanson, S. K., Kesik-Brodacka, M., Srivastava, S., Florens, L., Washburn, M. P., & Skowronski, J. (2011) · Nature · doi:10.1038/nature10195 · Cited by 1,200 · see citing works

Development of a self-inactivating lentivirus vector

Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196 · see citing works

In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination

Bonifaz, L. C., Bonnyay, D., Charalambous, A., Darguste, D. I., Fujii, S., Soares, H., Brimnes, M. K., Moltedo, B., Moran, T. M., & Steinman, R. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032220 · Cited by 921 · see citing works

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869 · see citing works

A quantitative assay for HIV DNA integration in vivo

Butler, S. L., Hansen, M. S., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 678 · see citing works

Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

Dhodapkar, M. V., Sznol, M., Zhao, B., Wang, D., Carvajal, R. D., Keohan, M. L., Chuang, E., Sanborn, R. E., Lutzky, J., Powderly, J. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008068 · Cited by 367 · see citing works

Dendritic Cells: Master Regulators of the Immune Response

Mellman, I. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0102 · Cited by 329 · see citing works

Enhanced Antigen-Specific Antitumor Immunity with Altered Peptide Ligands that Stabilize the MHC-Peptide-TCR Complex

Slansky, J. E., Rattis, F. M., Boyd, L. F., Fahmy, T. M., Jaffee, E. M., Schneck, J. P., Margulies, D. H., & Pardoll, D. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00052-2 · Cited by 308 · see citing works

Listeria -based cancer vaccines that segregate immunogenicity from toxicity

Brockstedt, D. G., Giedlin, M. A., Leong, M. L. L., Bahjat, K. S., Gao, Y. Q., Luckett, W. S., Liu, W., Cook, D. N., Portnoy, D. A., & Dubensky, T. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406035101 · Cited by 299 · see citing works

Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells

Wiskerchen, M. A., & Muesing, M. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.1.376-386.1995 · Cited by 271 · see citing works

Immunologic Basis of Vaccine Vectors

Liu, M. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.004 · Cited by 237 · see citing works

A Rev-Independent Human Immunodeficiency Virus Type 1 (HIV-1)-Based Vector That Exploits a Codon-Optimized HIV-1 gag-pol Gene

Kotsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M., & Mitrophanous, K. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4839-4852.2000 · Cited by 228 · see citing works

Engineered lentivector targeting of dendritic cells for in vivo immunization

Yang, L., Yang, H., Rideout, K., Cho, T., Joo, K. I., Ziegler, L., Elliot, A. M., Walls, A., Yu, D., Baltimore, D., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1390 · Cited by 208 · see citing works

Pathogen-Induced Inflammatory Environment Controls Effector and Memory CD8+ T Cell Differentiation

Obar, J. J., Jellison, E. R., Sheridan, B. S., Blair, D. A., Pham, Q.-M., Zickovich, J. M., & Lefrançois, L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102335 · Cited by 169 · see citing works

Widely Divergent Biochemical Properties of the Complete Set of Mouse DC-SIGN-related Proteins

Powlesland, A. S., Ward, E. M., Sadhu, S. K., Guo, Y., Taylor, M. E., & Drickamer, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601925200 · Cited by 166 · see citing works

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets

Wimmers, F., Schreibelt, G., Sköld, A. E., Figdor, C. G., & de Vries, I. J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00165 · Cited by 145 · see citing works

Rev-Independent Expression of Synthetic gag-pol Genes of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus: Implications for the Safety of Lentiviral Vectors

Wagner, R., Graf, M., Bieler, K., Wolf, H. J., Grunwald, T., Foley, P., & Überla, K. (2000) · Human Gene Therapy · doi:10.1089/104303400750038507 · Cited by 138 · see citing works

Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer

Gulley, J. L., Madan, R. A., Tsang, K. Y., Jochéms, C., Marté, J. L., Farsaci, B., Tucker, J. A., Hodge, J. W., Liewehr, D. J., Steinberg, S. M., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0108 · Cited by 136 · see citing works

Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field

Majhen, D., Calderón, H., Chandra, N., Fajardo, C. A., Rajan, A., Alemany, R., & Custers, J. H. H. V. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.235 · Cited by 102 · see citing works

A Large U3 Deletion Causes Increased In Vivo Expression from a Nonintegrating Lentiviral Vector

Bayer, M., Kantor, B., Cockrell, A., Ma, H., Zeithaml, B., Li, X., McCown, T., & Kafri, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.199 · Cited by 94 · see citing works

Induction and Measurement of Cytotoxic T Lymphocyte Activity

Wonderlich, J., Shearer, G. M., Livingstone, A. M., Brööks, A. G., Soloski, M. J., & Presby, M. M. (2018) · Current Protocols in Immunology · doi:10.1002/cpim.38 · Cited by 85 · see citing works

Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines

Madan, R. A., Bilušić, M., Heery, C. R., Schlom, J., & Gulley, J. L. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.010 · Cited by 84 · see citing works

Clinical applications of attenuated MVA poxvirus strain

Gómez, C. E., Perdiguero, B., García‐Arriaza, J., & Estéban, M. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.845531 · Cited by 73 · see citing works

Direct Presentation Is Sufficient for an Efficient Anti-Viral CD8+ T Cell Response

Xu, R.-H., Remakus, S., Ma, X., Roscoe, F., & Sigal, L. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000768 · Cited by 62 · see citing works

Notable Reduction in Illegitimate Integration Mediated by a PPT-deleted, Nonintegrating Lentiviral Vector

Kantor, B., Bayer, M., Ma, H., Samulski, J., Li, C., McCown, T., & Kafri, T. (2011) · Molecular Therapy · doi:10.1038/mt.2010.277 · Cited by 56 · see citing works

Combination of Alphavirus Replicon Particle–Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates

Avogadri, F., Zappasodi, R., Yang, A. S., Budhu, S., Malandro, N., Hirschhorn-Cymerman, D., Tiwari, S., Maughan, M. F., Olmsted, R. A., Wolchok, J. D., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0220 · Cited by 48 · see citing works

In vivo targeting of human DC ‐ SIGN drastically enhances CD 8+ T ‐cell‐mediated protective immunity

Hesse, C., Ginter, W., Förg, T., Mayer, C. T., Baru, A. M., Arnold‐Schrauf, C., Unger, W. W. J., Kalay, H., van Kooyk, Y., Berod, L., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201343429 · Cited by 41 · see citing works

Lentiviral Vectors for Anti-Tumor Immunotherapy

Breckpot, K., Emeagi, P. U., & Thielemans, K. (2008) · Current Gene Therapy · doi:10.2174/156652308786848058 · Cited by 40 · see citing works

Induction and Measurement of Cytotoxic T Lymphocyte Activity

Wonderlich, J., Shearer, G. M., Livingstone, A. M., & Brööks, A. G. (2006) · Current Protocols in Immunology · doi:10.1002/0471142735.im0311s72 · Cited by 40 · see citing works

Design of a Novel Integration-deficient Lentivector Technology That Incorporates Genetic and Posttranslational Elements to Target Human Dendritic Cells

Tareen, S. U., Kelley-Clarke, B., Nicolai, C. J., Cassiano, L., Nelson, L. T., Slough, M. M., Vin, C. D., Odegard, J., Sloan, D. D., Hoeven, N. V., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.278 · Cited by 32 · see citing works

Targeting DNGR‐1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas

Picco, G., Beatson, R., Taylor‐Papadimitriou, J., & Burchell, J. (2014) · European Journal of Immunology · doi:10.1002/eji.201344076 · Cited by 31 · see citing works

On the Role of Dendritic Cells Versus Other Cells in Inducing Protective CD8+ T Cell Responses

Zinkernagel, R. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00030 · Cited by 27 · see citing works

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection

Betts, G. J., Poyntz, H., Stylianou, E., Reyes‐Sandoval, A., Cottingham, M. G., Hill, A. V. S., & McShane, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050447 · Cited by 27 · see citing works

A Rev-Independent gag/pol Eliminates Detectable psi-gag Recombination in Lentiviral Vectors

Tareen, S. U., Nicolai, C. J., Campbell, D. J., Flynn, P., Slough, M. M., Vin, C. D., Kelley-Clarke, B., Odegard, J., & Robbins, S. H. (2013) · BioResearch open access · doi:10.1089/biores.2013.0037 · Cited by 8 · see citing works

Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines

van Dinther, D., Stolk, D. A., van de Ven, R., van Kooyk, Y., de Gruijl, T. D., & den Haan, J. M. M. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5mr0217-059rr · Cited by 87 · see citing works

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1

Somaiah, N., Block, M. S., Kim, J. W., Shapiro, G. I., Do, K. T., Hwu, P., Eder, J. P., Jones, R. L., Lu, H., ter Meulen, J. H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1025 · Cited by 87 · see citing works

Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through

Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H. (2022) · Biomedicines · doi:10.3390/biomedicines10010107 · Cited by 69 · see citing works

The old and the new: Prospects for non-integrating lentiviral vector technology

Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58 · see citing works

Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells

Lévy, C., Verhoeyen, E., & Cosset, F. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.08.003 · Cited by 45 · see citing works

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

Goyvaerts, C., & Breckpot, K. (2015) · Journal of Immunology Research · doi:10.1155/2015/785634 · Cited by 44 · see citing works

Physical Characterization and Stabilization of a Lentiviral Vector Against Adsorption and Freeze-Thaw

Kumru, O. S., Wang, Y., Gombotz, C. W. R., Kelley-Clarke, B., Cieplak, W., Kim, T. I., Joshi, S. B., & Volkin, D. B. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.07.010 · Cited by 40 · see citing works

LV305, a dendritic cell-targeting integration-deficient ZVex TM -based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response

Albershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.10 · Cited by 38 · see citing works

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Somaiah, N., Chawla, S. P., Block, M. S., Morris, J. C., Do, K. T., Kim, J. W., Druta, M., Sankhala, K. K., Hwu, P., Jones, R. L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1847846 · Cited by 35 · see citing works

Lewis Lung Cancer Cells Promote SIGNR1(CD209b)‐Mediated Macrophages Polarization Induced by IL‐4 to Facilitate Immune Evasion

Yan, X., Li, W., Pan, L., Fu, E., Xie, Y., Chen, M., & Mu, D. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25399 · Cited by 24 · see citing works

Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine

Albershardt, T. C., Parsons, A. J., Reeves, R. S., Flynn, P., Campbell, D. J., ter Meulen, J., & Berglund, P. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.02.034 · Cited by 23 · see citing works

HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells

Wee, E. G., Ondondo, B., Berglund, P., Archer, J. F., McMichael, A. J., Baltimore, D., ter Meulen, J. H., & Hanke, T. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.004 · Cited by 20 · see citing works

Dendritic cell–targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation

Kim, J. T., Liu, Y., Kulkarni, R. P., Lee, K. K., Dai, B., Lovely, G. A., Ouyang, Y., Wang, P., Yang, L., & Baltimore, D. (2017) · Science Immunology · doi:10.1126/sciimmunol.aal1329 · Cited by 19 · see citing works

Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8+ T Cells that Protect Against Subcutaneous B16-OVA Melanoma

Stark, F. C., McCluskie, M. J., & Krishnan, L. (2016) · Vaccines · doi:10.3390/vaccines4040044 · Cited by 14 · see citing works

Suppressed dendritic cell functions by cystatin C lead to compromised immunity in vivo

Chen, S., Liu, L., Zhang, W., Sun, L. J., Wang, F., Zhao, Y., Liu, S., Zhao, L., & Xu, Y. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104049 · Cited by 10 · see citing works

Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A

Lu, H., Betancur, A., Chen, M. J., & ter Meulen, J. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01438 · Cited by 11 · see citing works

Review on the Immunotherapy Strategies Against Metastatic Colorectal Carcinoma

Signorini, L., Delbue, S., Ferrante, P., & Bregni, M. (2016) · Immunotherapy · doi:10.2217/imt-2016-0045 · Cited by 10 · see citing works

Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors

Farley, D. C., McCloskey, L., Thorne, B. A., Tareen, S. U., Nicolai, C. J., Campbell, D. J., Bannister, R., Stewart, H. J., Pearson, L. J., Moyer, B., et al. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.17 · Cited by 9 · see citing works

The feasibility of incorporating Vpx into lentiviral gene therapy vectors

McAllery, S., Ahlenstiel, C., Suzuki, K., Symonds, G. P., Kelleher, A. D., & Turville, S. G. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.66 · Cited by 7 · see citing works

Immune evasion pathways and the design of dendritic cell-based cancer vaccines.

Hanks, B. A. (2016) · PubMed · Cited by 6 · see citing works

Design of a titering assay for lentiviral vectors utilizing direct extraction of DNA from transduced cells in microtiter plates

Murphy, M. E., Vin, C. D., Slough, M. M., Gombotz, W. R., & Kelley-Clarke, B. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.5 · Cited by 5 · see citing works

ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalities

Leleux, J. A., Albershardt, T. C., Parsons, A. J., ter Meulen, J., & Berglund, P. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.08.003 · Cited by 5 · see citing works

Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory

Leleux, J. A., Albershardt, T. C., Reeves, R. S., James, R. D., Krull, J. E., Parsons, A. J., ter Meulen, J., & Berglund, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259301 · Cited by 4 · see citing works

Investigating the feasibility of incorporating Vpx into lentiviral gene therapy vectors: at a global and targeted scale

McAllery, S. (2016) · The Sydney eScholarship Repository (The University of Sydney)

Unraveling the Potential Role of SIGNR1(CD209b) in Shaping Gut Microbiota During the Early Postnatal Life

Hasan, N., Zhu, S., & Chen, T. (2025) · Apmis · doi:10.1111/apm.70033

Safety and HBsAg reduction with a lentiviral vaccine J-51 in chronic hepatitis B: An investigator-initiated pilot trial

Song, J., Zhang, Q., Zhang, Y., Shen, J., Wei, R., Wang, K., Shen, C., Wang, W., Chu, M., Zhou, F., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201790

Design of a Novel Integration-deficient Lentivector Technology That Incorporates Genetic and Posttranslational Elements to Target Human Dendritic Cells

Tareen, S. U., Kelley-Clarke, B., Nicolai, C. J., Cassiano, L., Nelson, L. T., Slough, M. M., Vin, C. D., Odegard, J., Sloan, D. D., Hoeven, N. V., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.278 · Cited by 32 · see citing works

Homelessness and health

Daly, G. (1989) · Cities · doi:10.1016/0264-2751(89)90004-8 · Cited by 14 · see citing works

Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity

Hu, B., Dai, B., & Wang, P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.012 · Cited by 45 · see citing works

Abstract 702: DCVex(TM): A novel integration-deficient lentivector technology that incorporates genetic and post-translational elements to target dendritic cells

Tareen, S. U., Kelley-Clarke, B., Nicolai, C. J., Slough, M. M., Vin, C. D., Hoeven, N. V., Robbins, S. H., ter Meulen, J. H., & Berglund, P. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-702

Engineered lentivector targeting of dendritic cells for in vivo immunization

Yang, L., Yang, H., Rideout, K., Cho, T., Joo, K. I., Ziegler, L., Elliot, A. M., Walls, A., Yu, D., Baltimore, D., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1390 · Cited by 208 · see citing works